Clinical Report: Receptor Variability in Metastatic Breast Cancer

Overview

This study analyzes receptor discordance in metastatic breast cancer, revealing significant changes in estrogen, progesterone, and HER2 receptor expression between primary and metastatic lesions. The findings underscore the importance of reassessing receptor status to inform treatment decisions and improve patient outcomes.

Background

Breast cancer is the most commonly diagnosed cancer in women and poses a significant health threat, particularly when it progresses to metastatic disease. Understanding the variability in receptor expression between primary and metastatic sites is crucial for tailoring treatment strategies and improving prognostic predictions. This study highlights the necessity of reevaluating receptor status in metastatic lesions to optimize individualized care.

Data Highlights

Key Findings

• Receptor discordance rates were 25.1% for ER, 33.3% for PR, and 32.8% for HER2.
• PR showed the highest discordance, often transitioning from positive to negative.
• HER2 discordance was most pronounced in liver metastases (59.3%).
• Loss of hormone receptor or HER2 expression correlated with poorer overall survival.
• Reassessment of receptor status is essential for optimizing treatment strategies.

Clinical Implications

Clinicians should routinely reassess receptor status in metastatic breast cancer to guide treatment decisions effectively. The findings suggest that changes in receptor expression can significantly impact prognosis and survival outcomes, necessitating a personalized approach to therapy.

Conclusion

The study emphasizes the critical role of receptor variability in metastatic breast cancer and the need for ongoing evaluation of receptor status to enhance treatment efficacy and patient survival.

References

1. The ASCO Post, 2012 -- Next-generation Sequencing in Metastatic Triple-negative Breast Cancer Yields Rewards
2. The ASCO Post, 2022 -- Highlights From the 2021 San Antonio Breast Cancer Symposium Guest Editors
3. The ASCO Post, 2019 -- Regional Disparities in Metastatic Breast Cancer Survival Between 1990 and 2011
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), 2024
5. Journal of Gastroenterology — Genetic Diversity in Colon Cancer with Liver Metastasis
6. ASCO Biomarkers for Systemic Therapy in Metastatic Breast Cancer Guideline Summary
7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
8. ESMO Congress 2024 - Conference Calendar - ESMO Congress 2024